ProShares Ultra NASDAQ Biotechnology
21 hedge funds and large institutions have $4.52M invested in ProShares Ultra NASDAQ Biotechnology in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 7 closing their positions.
4.43% less ownership
Funds ownership: 9.1% → 4.67% (-4.4%)
5% less funds holding
Funds holding: 22 → 21 (-1)
12% less call options, than puts
Call options by funds: $1.29M | Put options by funds: $1.48M
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
45% less capital invested
Capital invested by funds: $8.2M → $4.52M (-$3.69M)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
+$862K |
| 2 |
WWM
Westwood Wealth Management
Los Angeles,
California
|
+$580K |
| 3 |
TCBWMS
Texas Capital Bank Wealth Management Services
Dallas,
Texas
|
+$290K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$13.8K |
| 5 |
S
SignatureFD
Atlanta,
Georgia
|
+$8.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IMC Chicago
Chicago,
Illinois
|
-$2.43M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.49M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.1M |
| 4 |
CCP
Clarity Capital Partners
Newport Beach,
California
|
-$201K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$113K |
BIB Hedge Fund Activity: Q1 2024 in Review
21 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q1 2024, worth a combined $4.52M — down 45% from $8.2M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BIB and 6 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 1 added.
The largest buyer was Toth Financial Advisory, adding an estimated $862K. The largest seller was IMC Chicago, exiting entirely with an estimated $2.43M sold.
- 21 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q1 2024, down from 22 in Q4 2023.
- Funds reported $4.52M of ProShares Ultra NASDAQ Biotechnology stock for Q1 2024, down 45% quarter-over-quarter.
- 6 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q1 2024 and 7 closed out, a net change of -1 holder.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q1 2024 was Toth Financial Advisory, an estimated $862K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q1 2024 was IMC Chicago, an estimated $2.43M sold.
Based on aggregated 13F filings for Q1 2024.